Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome

References

• Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Curr. Opin. Investig. Drugs6(10), 1012–1022 (2005).
   PubMedGoogle Scholar
• Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol.46(2), 325–340 (2003).
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril.81(1), 19–25 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Staks T, Jutting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception48(6), 557–575 (1993).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril.82(4), 893–902 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab.86(4), 1626–1632 (2001).
   PubMed Web of Science ®Google Scholar
• Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and Metabolic Effects of Rosiglitazone in Overweight Women with PCOS: a Randomized Placebo-Controlled Study. Human reproduction, Oxford, UK (2006).
   Google Scholar
• Zheng Z, Li M, Lin Y, Ma Y. Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi37(5), 271–273 (2002).
   PubMedGoogle Scholar
• Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril.79(3), 562–566 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang CL, Gao HY, Zhao ZG, Jia P. Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi39(3), 173–175 (2004).
   Google Scholar
• Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J. Soc. Gynecol. Invest.10(2), 99–104 (2003).
   PubMed Web of Science ®Google Scholar
• Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil. Steril.85(2), 428–435 (2006).
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum. Reprod. Update11(3), 277–291 (2005).
   PubMed Web of Science ®Google Scholar
• Venturoli S, Ravaioli B, Bagnoli A et al. Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients. Eur. J. Contracept. Reprod. Health Care3(1), 29–33 (1998).
   PubMedGoogle Scholar
• Tao Y, Dai Q, Zhang D. Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate. Zhonghua Fu Chan Ke Za Zhi34(9), 528–532 (1999).
   Google Scholar
• Yilmaz M, Karakoc A, Toruner FB et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol. Endocrinol.21(3), 154–160 (2005).
   PubMed Web of Science ®Google Scholar
• Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.89(8), 3835–3840 (2004).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N. Engl. J. Med.352(12), 1223–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynecol.18(5), 737–754 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod.13(10), 2706–2711 (1998).
   PubMed Web of Science ®Google Scholar
• Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Int. J. Gynaecol. Obstet.87(1), 29–33 (2004).
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum. Reprod.16(1), 36–42 (2001).
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynecologists. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists: number 41, December 2002. Obstet. Gynecol.100(6), 1389–1402 (2002).
   PubMedGoogle Scholar
• Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab.88(9), 4116–4123 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology196(1), 43–46 (1998).
   PubMed Web of Science ®Google Scholar
• Romualdi D, Guido M, Ciampelli M et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod.18(6), 1210–1218 (2003).
   PubMed Web of Science ®Google Scholar
• Tan J. Hormonal treatment of acne: review of current best evidence. J. Cutan. Med. Surg.8(Suppl. 4), 11–15 (2004).
   Google Scholar
• Lynde CW. Hormonal approach to the treatment of acne: a Canadian perspective. J. Cutan. Med. Surg.8(Suppl. 4), 1–2 (2004).
   Google Scholar
• Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin. Endocrinol. (Oxf.)57(2), 231–234 (2002).
   PubMed Web of Science ®Google Scholar
• Checa MA, Requena A, Salvador C et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum. Reprod. Update11(4), 375–390 (2005).
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab.84(1), 165–169 (1999).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes41(10), 1257–1266 (1992).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes51(9), 2796–2803 (2002).
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J. Clin. Endocrinol. Metab.90(1), 60–65 (2005).
   PubMed Web of Science ®Google Scholar
• Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur. J. Endocrinol.153(1), 115–121 (2005).
   PubMed Web of Science ®Google Scholar
• Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab.82(9), 3074–3077 (1997).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab.85(9), 3161–3168 (2000).
   PubMed Web of Science ®Google Scholar
• Rimm EB, Manson JE, Stampfer MJ et al. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia35(10), 967–972 (1992).
   PubMed Web of Science ®Google Scholar
• Chasan-Taber L, Willett WC, Stampfer MJ et al. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care20(3), 330–335 (1997).
   PubMed Web of Science ®Google Scholar
• Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum. Reprod.21(1), 121–128 (2006).
   PubMed Web of Science ®Google Scholar
• Talbott EO, Guzick DS, Sutton-Tyrrell K et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol.20(11), 2414–2421 (2000).
   PubMed Web of Science ®Google Scholar
• Guzick DS. Cardiovascular risk in women with polycystic ovarian syndrome. Semin. Reprod. Endocrinol.14(1), 45–49 (1996).
   PubMedGoogle Scholar
• Yilmaz M, Bukan N, Ayvaz G et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum. Reprod.20(12), 3333–3340 (2005).
   PubMed Web of Science ®Google Scholar
• Kilicdag EB, Bagis T, Zeyneloglu HB et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum. Reprod.20(4), 894–899 (2005).
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception73(4), 348–351 (2006).
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med.354(15), 1567–1577 (2006).
   PubMed Web of Science ®Google Scholar
• Turner RC, Holman RR, Stratton IM et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• WHO. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Lancet349(9060), 1202–1209 (1997).
   PubMed Web of Science ®Google Scholar
• Tanis BC, van den Bosch MA, Kemmeren JM et al. Oral contraceptives and the risk of myocardial infarction. N. Engl. J. Med.345(25), 1787–1793 (2001).
   PubMed Web of Science ®Google Scholar
• Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners’ oral contraception study. Br. Med. J.318(7176), 96–100 (1999).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab.90(7), 3863–3870 (2005).
   PubMed Web of Science ®Google Scholar
• Bermont L, Lamielle F, Lorchel F et al. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J. Clin. Endocrinol. Metab.86(1), 363–368 (2001).
   PubMed Web of Science ®Google Scholar
• Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am. J. Obstet. Gynecol.179(1), 6–12 (1998).
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br. J. Cancer89(9), 1697–1704 (2003).
   Google Scholar
• Lukanova A, Zeleniuch-Jacquotte A, Lundin E et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int. J. Cancer108(2), 262–268 (2004).
   PubMed Web of Science ®Google Scholar
• Gamayunova VB, Bobrov Y, Tsyrlina EV, Evtushenko TP, Berstein LM. Comparative study of blood insulin levels in breast and endometrial cancer patients. Neoplasma44(2), 123–126 (1997).
   PubMedGoogle Scholar
• Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes. Metab.1(3), 165–172 (1999).
   PubMed Web of Science ®Google Scholar
• St John SM, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care25(11), 2058–2064 (2002).
   PubMed Web of Science ®Google Scholar
• Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK general practice research database. Pharmacoepidemiol. Drug Saf.13(7), 427–436 (2004).
   PubMed Web of Science ®Google Scholar
• Kalyoncu NI, Yaris F, Ulku C et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod.Toxicol.19(4), 563–564 (2005).
   PubMed Web of Science ®Google Scholar
• Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod.Toxicol.18(4), 619–621 (2004).
   PubMed Web of Science ®Google Scholar
• Regidor PA, Speer K, Regidor M, Schindler EM. Long-term side-effects following cyproterone acetate containing therapy in gynecology. Zentralbl.Gynakol.122(5), 268–273 (2000).
   PubMedGoogle Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br. Med. J.327(7421), 951–953 (2003).
   PubMed Web of Science ®Google Scholar
• Cataldo NA, Abbasi F, McLaughlin TL et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum. Reprod.21(1), 109–120 (2006).
   PubMed Web of Science ®Google Scholar
• Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr. J.52(3), 299–308 (2005).
   PubMed Web of Science ®Google Scholar
• Lv L, Liu Y. Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. J. Huazhong. Univ. Sci. Technolog. Med. Sci.24(5), 480–482 (2004).
   Google Scholar